Annual Medicare ESRD Rule Highlights Innovation and “Meaningful Measures”
Last week, the Centers for Medicare & Medicaid Services (CMS) proposed what they called “innovative changes” to the payment rule for the End-Stage Renal Disease (ESRD) program. The rule includes a “proposal to address new renal dialysis drug and biological costs and foster innovations in treatment by incentivizing new therapies for patients on dialysis and a proposal to reduce facility-related documentation burden.” It contains the first changes to the ESRD Quality Incentive Program (QIP) since last year’s announcement of CMS’ “Meaningful Measures” Initiative. Funding for Dialysis The proposed 2019 ESRD base rate is $235.82, an increase of $3.45 to the current [...]